

Please amend the application as follows:

In the Specification

Please replace the paragraph at page 4, lines 12 through 18 with the following paragraph:

E1  
Preferably, the vaccine composition includes at least one antigen which comprises a T cell epitope, and the T cells are T cell clones which are specific for a T cell epitope in at least one of the antigens. In one embodiment, the T cells are CD8+ T cells and the vaccine composition includes at least one antigen comprising a CD8 epitope. In this embodiment, the T cell response to the processed antigen can be, for example, T cell proliferation, cytolysis of the antigen presenting cells or the production of one or more cytokines.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

In the Claims

Please cancel all Claims 1, 4-8, 11, 17 and 20-23.

Please add New Claims 24-35.

- E2
24. (New) A method for assessing the ability of a vaccine composition in a group consisting of two or more distinct vaccine compositions each having one or more nucleic acid molecules encoding one or more antigens which comprise the same T cell epitope, to stimulate a monoclonal human T cell response, said method comprising the steps of:
- (a) contacting human antigen presenting cells in culture with the vaccine composition, thereby, if one or more of the nucleic acid molecules are taken up and processed by said antigen presenting cells, producing one or more processed antigens;
  - (b) contacting said antigen presenting cells of step (a) with monoclonal human T cells having a T cell receptor specific for the peptide encoded by said nucleic acid molecule(s) encoding one or more antigens which comprise said T cell epitope